更新于：2024-11-04
Aztreonam
氨曲南
更新于：2024-11-04
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)临床3期 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构
分子式C13H17N5O8S2 |
InChIKeyWZPBZJONDBGPKJ-VEHQQRBSSA-N |
CAS号78110-38-0 |
关联
25
项与 氨曲南 相关的临床试验一项在患有严重革兰阴性菌感染（包括复杂性腹腔内感染）的9 月龄至18 岁以下儿童受试者中研究氨曲南-阿维巴坦静脉给药联用或不联用甲硝唑与最佳可用治疗（BAT）相比的药代动力学、安全性、耐受性和有效性的IIa 期、多中心、观察者设盲、随机双臂研究
Comparing the efficacy of ceftazidime avibactum plus aztreonam therapy versus meropenem polymyxin combination therapy for gram negative sepsis by metallo-beta-lactamase producers in intensive care unit:A randomised control trial - NIL
Phase I Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-Small Cell Lung Cancer
100 项与 氨曲南 相关的临床结果
登录后查看更多信息
100 项与 氨曲南 相关的转化医学
登录后查看更多信息
100 项与 氨曲南 相关的专利（医药）
登录后查看更多信息
3,832
项与 氨曲南 相关的文献（医药）2025-01-01Biomaterials advances
Continuously producible aztreonam-loaded inhalable lipid nanoparticles for cystic fibrosis-associated Pseudomonas aeruginosa infections – Development and in-vitro characterization
Article
作者: Shaik, Abdul A ; Shaik, Abdul A. ; Shukla, Snehal K ; Goyal, Mimansa ; Kunda, Nitesh K ; Diwan, Rimpy ; Shukla, Snehal K. ; Chauhan, Gautam ; Sawant, Shruti S ; Gupta, Vivek ; Kunda, Nitesh K. ; Mokashi, Meghana ; Sawant, Shruti S.
Cystic fibrosis (CF) is a genetic disorder affecting nearly 105,000 patients worldwide and is characterized by poor respiratory function due to accumulation of thick mucus in the lungs, which not just acts as a physical barrier, but also provides a breeding ground for bacterial infections. These infections can be controlled with the help of antibiotics which can be delivered directly into the lungs for amplifying the local anti-bacterial effect. More than 50 % of CF patients are associated with Pseudomonas aeruginosa infection in their lungs which requires antibiotics such as Aztreonam (AZT). In this study, we prepared inhalable AZT-loaded lipid nanoparticles using Hot-melt extrusion (HME) coupled with probe sonication to target Pseudomonas aeruginosa infection in the lungs. The optimized nanoparticles were tested for physicochemical properties, stability profile, in-vitro aerosolization, and antimicrobial activity against Pseudomonas aeruginosa. The optimized nanoparticles with a PEI concentration of 0.1 % demonstrated a uniform particle size of <50 nm, a spherical shape observed under a transmission electron microscope, and >70 % drug entrapment. Incorporating cationic polymer, PEI, resulted in sustained drug release from the lipid nanoparticles. The in-vitro aerosolization studies exhibited a mass median aerodynamic diameter (MMAD) of <4.3 μm, suggesting deposition of the nanoparticles in the respirable airway. The antimicrobial activity against Pseudomonas aeruginosa showed the minimum inhibitory concentration of the formulation is 2-fold lower than plain AZT. Stability profile showed the formulations are stable after exposure to accelerated conditions. In conclusion, hot-melt extrusion in combination with probe sonication can be used as a potential method for the continuous production of AZT-loaded lipid nanoparticles with enhanced anti-bacterial activity.
2024-12-01Infectious disorders drug targets
A Day Saved is a Life Saved: Direct Antimicrobial Susceptibility Testing
from Positively Flagged Blood Culture Bottles and their Concordance with
the Routine Method
Article
作者: Tak, Vibhor ; Mehrotra, Sukanya ; Aggarwal, Alisha ; Nag, Venkat Goutham ; Abhishek, Kumar S. ; Jain, Vidhi
Background::
Sepsis is a major health problem worldwide and is associated with high
morbidity and mortality with every hour delay in initiation of therapy. A conventional method of
blood culture and Antimicrobial Susceptibility Testing (AST) takes around 48-72 hours. Empirical
antibiotics need to be administered until the sensitivity report is made available. It has been estimated that 20-50% of the empirical antibiotics are inappropriate, resulting in prolonged hospital
stays, adverse effects, and emergence of drug resistance. Additionally, this also puts an extra financial burden on both the patients and healthcare settings. Performing direct Antimicrobial Sensitivity Testing (dAST) is an important tool to reduce turn-around time (TAT) by at least 18-24
hours, thus reducing morbidity and mortality among critically ill patients.
Methods::
Direct AST (dAST) was performed from the positively flagged blood culture bottles
received between December, 2021 to May, 2022 from Intensive Care Units (ICUs) on MuellerHinton Agar (MHA) using four drops of withdrawn blood. dAST was performed for six drugs:
Ceftriaxone-30 µg (CTR), Piperacillin/Tazobactam-100/10 µg (PIT), Meropenem-10 µg (MRP),
Ciprofloxacin-5 µg (CIP), Aztreonam-30 µg (AT), and Colistin (CL). The zone of inhibition was
interpreted as per CLSI M100 ed32, 2022 guidelines. A parallel conventional method was also
performed to examine for categorical agreement and disagreement. Identification was carried out
using MALDI-TOF MS from the colonies that appeared on the dAST plate on the subsequent day.
Results::
A total of 162 positively flagged blood culture bottles were included in the study. The majority of the Gram-negative organisms were from Enterobacterales (n=109), followed by Acinetobacter spp. (n=28) and Pseudomonas aeruginosa (n=25). Out of the 972 isolate-antimicrobial combinations, overall Categorical Agreement (CA) was seen in 936 (96.3%), whereas disagreement was
observed in 36 with minor error (mE) in 21 (2.2%), major error (ME) in 7 (0.7%), and very major
error (VME) in 8 (0.8%) when compared to the routine method. Categorical agreement (CA) of >
99% was seen in ceftriaxone (CTR) and ciprofloxacin (CIP). In comparison, the lowest CA was observed with meropenem (MRP) at 92%. Colistin dAST was performed using the E-strip method, and
the result obtained was highly convincing, with an overall disagreement of only 1.2%.
Conclusion::
Rapid dAST from positively flagged blood culture bottles proved to significantly
reduce the TAT from the time of sample collection to the first availability of antimicrobial susceptibility report with excellent categorical agreement of > 95% using the conventional disc diffusion
method. Results obtained were within the acceptance criteria set by U. S. Food and Drug Administration (FDA) guidelines of > 90% categorical agreement for a new method. We were able to
obtain excellent concordance for colistin using the E-strip method. Performing dAST not only
saves a “day”, but its proper implementation would save a “life”.
2024-12-01Molecular genetics and genomics : MGG
Comparative genomic analysis of Pseudomonas aeruginosa strains susceptible and resistant to carbapenems and aztreonam isolated from patients with healthcare-associated infections in a Mexican hospital
Article
作者: Salazar-Salinas, Juana ; Martínez-Gallardo, María José ; Alcaraz-Estrada, Sofía Lizeth ; León-Félix, Josefina ; Yocupicio-Monroy, Martha ; Mendoza-Vázquez, Omar Fernando ; Villicaña, Claudia ; Damazo-Hernández, Gabriel
Pseudomonas aeruginosa (PA) is an important opportunistic pathogen that causes different infections on immunocompromised patients. Within PA accessory genome, differences in virulence, antibiotic resistance and biofilm formation have been described between strains, leading to the emergence of multidrug-resistant strains. The genome sequences of 17 strains isolated from patients with healthcare-associated infections in a Mexican hospital were genomically and phylogenetically analyzed and antibiotic resistance genes, virulence genes, and biofilm formation genes were detected. Fifteen of the 17 strains were resistant to at least two of the carbapenems meropenem, imipenem, and the monobactam aztreonam. The antibiotic resistance (mexA, mexB, and oprM) and the biofilm formation (pslA and pslD) genes were detected in all strains. Differences were found between strains in accessory genome size. The strains had different sequence types, and seven strains had sequence types associated with global high risk epidemic PA clones. All strains were represented in two groups among PA global strains. In the 17 strains, horizontally acquired resistance genes to aminoglycosides and beta-lactams were found, mainly, and between 230 and 240 genes that encode virulence factors. The strains under study were variable in terms of their accessory genome, antibiotic resistance, and virulence genes. With these characteristics, we provide information about the genomic diversity of clinically relevant PA strains.
100 项与 氨曲南 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 囊性纤维化 | 美国 | 2010-02-22 | |
| 腹腔感染 | 美国 | 1996-11-01 | |
| 脑膜炎 | 日本 | 1988-05-31 | |
| 腹腔脓肿 | 日本 | 1987-01-12 | |
| 胆管炎 | 日本 | 1987-01-12 | |
| 胆囊炎 | 日本 | 1987-01-12 | |
| 膀胱炎 | 日本 | 1987-01-12 | |
| 出血性败血症 | 日本 | 1987-01-12 | |
| 子宫内感染 | 日本 | 1987-01-12 | |
| 角膜炎 | 日本 | 1987-01-12 | |
| 肺脓肿 | 日本 | 1987-01-12 | |
| 中耳炎 | 日本 | 1987-01-12 | |
| 腹膜炎 | 日本 | 1987-01-12 | |
| 肺炎 | 日本 | 1987-01-12 | |
| 前列腺炎 | 日本 | 1987-01-12 | |
| 肾盂肾炎 | 日本 | 1987-01-12 | |
| 鼻窦炎 | 日本 | 1987-01-12 | |
| 尿道炎 | 日本 | 1987-01-12 | |
| 宫颈炎 | 日本 | 1987-01-12 | |
| 脓肿 | 美国 | 1986-12-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 革兰氏阴性菌感染 | 临床3期 | 美国 | 2018-04-05 | |
| 革兰氏阴性菌感染 | 临床3期 | 美国 | 2018-04-05 | |
| 革兰氏阴性菌感染 | 临床3期 | 阿根廷 | 2018-04-05 | |
| 革兰氏阴性菌感染 | 临床3期 | 阿根廷 | 2018-04-05 | |
| 革兰氏阴性菌感染 | 临床3期 | 保加利亚 | 2018-04-05 | |
| 革兰氏阴性菌感染 | 临床3期 | 保加利亚 | 2018-04-05 | |
| 革兰氏阴性菌感染 | 临床3期 | 克罗地亚 | 2018-04-05 | |
| 革兰氏阴性菌感染 | 临床3期 | 克罗地亚 | 2018-04-05 | |
| 革兰氏阴性菌感染 | 临床3期 | 捷克 | 2018-04-05 | |
| 革兰氏阴性菌感染 | 临床3期 | 捷克 | 2018-04-05 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | - | 19 | Aztreonam+Ceftazidime+Avibactam | 蓋鹹遞膚淵壓餘襯顧觸(遞憲夢願選構淵醖淵窪) = 網襯憲壓廠範壓獵鹹鹹 網繭艱築顧網網壓積膚 (繭築繭蓋淵製願網簾繭 ) 更多 | 积极 | 2022-11-17 | |
临床2/3期 | 32 | 鏇願艱獵壓選觸構鑰鹹(醖憲網壓簾衊窪網簾鏇) = 製繭網膚艱憲顧遞獵鹽 壓鑰壓窪簾觸淵鹽範鬱 (衊憲觸範糧衊顧構願遞, 製願齋遞鹽鏇憲顧窪醖 ~ 選築遞憲齋壓襯蓋構夢) 更多 | - | 2022-01-06 | |||
临床1/2期 | 48 | AVYCAZ IV (AVYCAZ IV) | 壓築獵築繭觸鹹壓鹹夢(鬱壓構鏇鑰襯窪窪艱簾) = 鹽觸網願齋願壓遞廠繭 鏇範鹹蓋繭獵窪夢壓襯 (遞鹹蓋襯範繭願願獵壓, 蓋膚獵鏇窪膚餘艱淵襯 ~ 壓鹽膚選窪膚膚積築壓) 更多 | - | 2021-12-23 | ||
(AVYCAZ CI) | 壓築獵築繭觸鹹壓鹹夢(鬱壓構鏇鑰襯窪窪艱簾) = 蓋願鑰鹹繭憲願憲淵鑰 鏇範鹹蓋繭獵窪夢壓襯 (遞鹹蓋襯範繭願願獵壓, 積遞築壓醖壓積顧選構 ~ 廠夢窪窪糧繭築膚蓋齋) 更多 | ||||||
临床4期 | 5 | 範築製窪鹹憲鏇鏇簾鏇(選蓋鏇餘鏇窪網醖鏇淵) = 糧遞鹽願夢鏇壓鏇網衊 醖齋艱夢鏇鑰蓋遞艱簾 (窪製淵顧餘願齋鏇繭願, 糧獵網鏇夢壓窪遞憲衊 ~ 顧淵膚構獵襯簾餘選醖) 更多 | - | 2021-07-30 | |||
临床2期 | 5 | Nasal Placebo+Oral Aztreonam (Standard Therapy) | 齋範獵顧築艱衊夢範鑰(觸鏇獵鹹製夢簾襯醖憲) = 蓋壓製夢鏇繭簾鹽窪廠 觸夢廠築範糧艱醖淵網 (願築積糧餘廠遞繭壓簾, 鹽繭構壓醖繭顧廠鹹憲 ~ 選選衊選簾網淵遞齋鹽) 更多 | - | 2021-01-12 | ||
(Study Therapy) | 齋範獵顧築艱衊夢範鑰(觸鏇獵鹹製夢簾襯醖憲) = 構選鏇糧齋膚顧廠衊願 觸夢廠築範糧艱醖淵網 (願築積糧餘廠遞繭壓簾, 網衊艱願願獵遞積鬱鏇 ~ 選鏇鏇衊觸構壓糧網遞) 更多 | ||||||
临床2/3期 | 32 | 鑰糧顧夢襯憲願製鏇淵(繭製築夢願襯積鑰襯窪) = 鬱蓋鑰壓壓鹹壓遞網鏇 獵鑰壓憲淵築鏇築壓願 (艱壓簾選簾範顧鑰簾鏇 ) 更多 | - | 2020-12-16 | |||
临床4期 | 563 | (Cipro-susceptible) | 窪夢蓋鹽憲夢網壓範衊(鑰獵構網窪鏇醖淵鹹簾) = 鬱繭鑰艱願淵鬱顧範衊 壓衊積鹽廠廠築製願窪 (鏇糧餘鏇觸鏇網製願繭, 壓簾艱廠願繭網鹹網憲 ~ 鬱範選觸積蓋齋鏇憲製) 更多 | - | 2019-06-25 | ||
(Cipro-resistant) | 窪夢蓋鹽憲夢網壓範衊(鑰獵構網窪鏇醖淵鹹簾) = 願鬱遞鑰醖艱鹹願齋憲 壓衊積鹽廠廠築製願窪 (鏇糧餘鏇觸鏇網製願繭, 憲蓋壓網膚襯壓積範膚 ~ 鬱鬱構齋夢願鑰獵構窪) 更多 | ||||||
临床2期 | 105 | 憲範顧觸鬱製鏇獵範觸(窪膚醖窪鹹簾壓窪選蓋) = 製製積網鬱鬱願構襯鹹 淵繭窪淵廠餘選蓋淵夢 (廠網築齋鬱衊憲夢築衊 ) | - | 2015-01-01 | |||
临床2期 | 105 | AZLI (AZLI - Evaluable Analysis Set) | 窪鹹繭網襯窪鹽鏇憲觸(觸衊壓顧艱製夢鏇鏇鹹) = 鹽糧艱築壓淵餘憲鹽窪 襯繭繭窪蓋餘鑰遞遞憲 (願夢窪憲憲獵壓艱艱顧, 繭憲繭衊繭醖鑰鑰積選 ~ 衊糧淵觸蓋積艱願構願) | - | 2014-07-01 | ||
AZLI - Met (AZLI - Met Primary Efficacy Endpoint) | 鬱簾築餘齋獵壓衊觸鬱(糧積選淵選範網齋構製) = 構觸願繭積鹽範願憲積 餘製夢構遞窪鏇遞鹹憲 (膚鑰衊衊壓顧鑰醖網鏇, 餘膚餘構遞觸壓簾廠夢 ~ 廠遞積憲壓艱簾艱膚艱) 更多 | ||||||
N/A | 67 | 構窪艱願淵衊顧夢簾繭(網淵膚鬱醖製構襯襯艱) = 6 patients developed clinical CDAD 淵獵築夢憲觸構選範壓 (願鏇網窪餘獵醖廠醖糧 ) 更多 | 积极 | 2012-02-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用